74252
document
[ Therapeutic value of a combination of trimetazidine with a calcium inhibitor in the treatment of chronic coronary insufficiency ] . This double-blind , placebo-controlled study sought to examine the short-term benefit of adding 60 mg of trimetazidine to the daily therapeutic regimen of 29 male patients with coronary insufficiency who had persistent ST depression on exercise tolerance test ( greater than or equal to 1 mm ) , despite treatment with nifedipine 40 mg per day . As compared with the placebo group , after only 14 days , the patients treated with trimetazidine showed statistically significant increases in the maximum workload level attained before ST depression occurred ( 31 % versus - 6 % ; P = 0.009 ) , the total work performed ( 31 % versus 2 % ; P = 0.024 ) and a significant decrease in the systolic tension time ( double product ) /workload ratio ( -5 % versus +11 % ; P = 0.005 ) . Throughout the study the clinical acceptability was excellent , with no side effects attributable to trimetazidine being recorded . This study shows that the addition of trimetazidine to a calcium antagonist brings a valuable improvement in therapeutic results .
74253
Intervention_Pharmacological
trimetazidine
74254
Intervention_Pharmacological
trimetazidine
74255
Intervention_Pharmacological
nifedipine
74256
Intervention_Control
placebo
74257
Outcome_Physical
maximum workload level attained before ST depression
74258
Outcome_Physical
the total work performed
74259
Outcome_Physical
systolic tension time
74260
Participant_Condition
chronic coronary insufficiency ]
74261
Participant_Sample-size
29
74262
Participant_Sex
male
74263
Participant_Condition
coronary insufficiency
74264
Participant_Condition
persistent ST depression